Regulatory approval

Published by the Health Service Executive. Approved

As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

This is written in the approval document.

Reimbursement

CDS

Citation

Ibrutinib Therapy - Mantle Cell Lymphoma, 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6953/297_Ibrutinib_MCL.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	t(11;14)	Mantle Cell Lymphoma	Ibrutinib
HSE (1)	CCND1	Mantle Cell Lymphoma	Ibrutinib

Contributions

Date	Contributor	Description
2026-08-02	Van Allen lab	Initial curation of into moalmanac-db
2026-07-29	Health Service Executive	Indication approved for reimbursement.